Steve builds strong relationships with clients by being responsive to their needs and developing strategies tailored to those needs. Steve uses his Ph.D. in pharmacology and his experience in molecular biology, cancer biology, immunology and agricultural biotechnology to provide his clients with the knowledge and guidance they seek throughout the life of their patent portfolios. Steve Schilling is a member of Alston & Bird’s Intellectual Property – Patents Group. Steve focuses his practice on all services relating to biotechnology and life sciences patents, including patent application drafting and prosecution, patent counseling and strategic planning, and opinions on patentability, validity, noninfringement, and freedom to operate. Steve has a technical background in cell and molecular biology, genetics, cell signaling, cancer biology, and agricultural biotechnology. He has extensive experience drafting and prosecuting patent applications in technologies including genome editing, CRISPR-Cas, transgenic organisms, immunotherapies, gene therapies, and diagnostics. He manages extensive domestic and international patent portfolios for leading biopharmaceutical companies, biotechnology companies, and universities. Steve received his A.B. in biophysical chemistry, summa cum laude, from Dartmouth College, where he was awarded the Chandler T. White 1916 Research Prize for his research on photorespiration in Arabidopsis. He received his Ph.D. in pharmacology from Duke University, where he was awarded a National Science Foundation Graduate Research Fellowship and coauthored several book chapters and journal publications. Steve received his J.D., magna cum laude, from the Duke University School of Law. While at Duke Law, he served on the board of directors of the Intellectual Property and Cyberlaw Society and on the editorial board of the Duke Law Journal. Steve has been recognized by The Best Lawyers in America© as “One to Watch” in Patent Law for 2022.